A case of tamoxifen-induced hypertriglyceridemia monitoring the changes in lipoprotein fractions over time

• Main Authors: Hayato Isobe, Masashi Shimoda, Yuki Kan, Fuminori Tatsumi, Yukino Katakura, Tomohiko Kimura, Atsushi Obata, Kenji Kohara, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
• Format: Article
• Language: English
• Published: BMC 2021-06-01
• Series: BMC Endocrine Disorders
• Subjects: Tamoxifen; Hypertriglyceridemia; Lipoprotein fraction; Type 2 diabetes
• Online Access: https://doi.org/10.1186/s12902-021-00780-z

Abstract Background Tamoxifen, which is one of the selective estrogen receptor modulators (SERMs), can bring out life-threatening complication, e.g. hypertriglyceridemia-induced acute pancreatitis, although it is rare. We precisely report changes in lipoprotein metabolism before and after tamoxifen discontinuation because there have been few reports of it. Case presentation 47-year-old premenopausal woman with dyslipidemia, type 2 diabetes, nonalcoholic fatty liver disease and chronic kidney disease was prescribed tamoxifen as adjuvant therapy after operation of breast cancer. She experienced severe tamoxifen-induced hypertriglyceridemia several months after dosing tamoxifen. Before cessation of tamoxifen, lipoprotein fraction test revealed marked stagnation of VLDL and IDL metabolisms, resulting in severe hypertriglyceridemia (serum triglyceride level was 1881 mg/dL). Seven days after tamoxifen withdrawal, lipoprotein fraction test showed that the metabolisms of endogenous lipoproteins were changed drastically. Conclusions From these results, we confirmed that tamoxifen certainly changes lipoprotein metabolism through suppression of post-heparin lipolytic activity. It is very important to evaluate the balance between benefit and risk before dosing tamoxifen and survey lipid profiles constantly during treatment to avoid life-threatening complication when prescription of tamoxifen is planned.